Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany.
Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany.
Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.
Increasing the yield and the productivity in cell culture-based vaccine manufacturing using high-cell-density (HCD) cultivations faces a number of challenges. For example, medium consumption should be low to obtain a very high concentration of viable host cells in an economical way but must be balanced against the requirement that accumulation of toxic metabolites and limitation of nutrients have to be avoided. HCD cultivations should also be optimized to avoid unwanted induction of apoptosis or autophagy during the early phase of virus infection. To realize the full potential of HCD cultivations, a rational analysis of the cultivation conditions of the appropriate host cell line together with the optimal infection conditions for the chosen viral vaccine strain needs to be performed for each particular manufacturing process. We here illustrate our strategy for production of the modified vaccinia Ankara (MVA) virus isolate MVA-CR19 in the avian suspension cell line AGE1.CR.pIX at HCD. As a first step we demonstrate that the adjustment of the perfusion rate strictly based on the measured cell concentration and the glucose consumption rate of cells enables optimal growth in a 0.8 L bioreactor equipped with an ATF2 system. Concentrations up to 57 × 10 cells/mL (before infection) were obtained with a viability exceeding 95%, and a maximum specific cell growth rate of 0.019 h (doubling time = 36.5 h). However, not only the cell-specific MVA-CR19 virus yield but also the volumetric productivity was reduced compared to infections at conventional-cell-density (CCD). To facilitate optimization of the virus propagation phase at HCD, a larger set of feeding strategies was analyzed in small-scale cultivations using shake flasks. Densities up to 63 × 10 cells/mL were obtained at the end of the cell growth phase applying a discontinuous perfusion mode (semi-perfusion) with the same cell-specific perfusion rate as in the bioreactor (0.060 nL/(cell d)). At this cell concentration, a medium exchange at time of infection was required to obtain expected virus yields during the first 24 h after infection. Applying an additional fed-batch feeding strategy during the whole virus replication phase resulted in a faster virus titer increase during the first 36 h after infection. In contrast, a semi-continuous virus harvest scheme improved virus accumulation and recovery at a rather later stage of infection. Overall, a combination of both fed-batch and medium exchange strategies resulted in similar cell-specific virus yields as those obtained for CCD processes but 10-fold higher MVA-CR19 titers, and four times higher volumetric productivity.
在基于细胞培养的疫苗生产中,提高产量和生产力,使用高密度(HCD)培养面临许多挑战。例如,为了以经济的方式获得非常高浓度的存活宿主细胞,培养基消耗应该很低,但必须平衡积累有毒代谢物和限制营养物质的要求。HCD 培养也应进行优化,以避免在病毒感染的早期阶段发生不必要的细胞凋亡或自噬。为了充分发挥 HCD 培养的潜力,需要针对每种特定的生产工艺,对适当的宿主细胞系的培养条件进行合理分析,并对所选病毒疫苗株的最佳感染条件进行优化。在这里,我们举例说明了我们在 HCD 下使用禽悬浮细胞系 AGE1.CR.pIX 生产改良痘苗安卡拉(MVA)病毒株 MVA-CR19 的策略。作为第一步,我们证明了根据测量的细胞浓度和细胞的葡萄糖消耗率严格调整灌注率,可以在配备 ATF2 系统的 0.8 L 生物反应器中实现最佳生长。在感染前,可获得高达 57×10 个细胞/mL(细胞浓度)的浓度,存活率超过 95%,最大比细胞生长速率为 0.019 h(倍增时间=36.5 h)。然而,与在常规细胞密度(CCD)下的感染相比,不仅细胞特异性的 MVA-CR19 病毒产量,而且体积生产率也降低了。为了便于在 HCD 下优化病毒繁殖阶段,我们在摇瓶中进行了小规模培养,分析了更大的一组进料策略。在细胞生长阶段结束时,采用与生物反应器中相同的细胞特异性灌注率(0.060 nL/(细胞·d))的不连续灌注模式(半灌注),可获得高达 63×10 个细胞/mL 的密度。在这个细胞浓度下,在感染时需要进行培养基交换,以在感染后 24 小时内获得预期的病毒产量。在整个病毒复制阶段应用额外的补料分批进料策略,可在感染后 36 小时内导致病毒滴度更快增加。相比之下,半连续病毒收获方案可改善感染后期的病毒积累和恢复。总体而言,补料分批和培养基交换策略的结合可产生与 CCD 工艺相同的细胞特异性病毒产量,但 MVA-CR19 滴度高 10 倍,体积生产率高 4 倍。